BACKGROUND: The brother of the regulator of imprinted sites (BORIS) is a novel member of the cancer testis antigen gene family, which are normally expressed only in spermatocytes, but abnormally activated in different malignancies. AIM: The aim of this study was to explore the expression of BORIS in hepatocellular carcinoma (HCC) and its correlation with the clinicopathologic features and prognosis of HCC. METHODS: We investigated BORIS expression in HCC cell lines and 105 primary HCC clinical surgical specimens using real-time polymerase chain reaction and Western blot analysis. We further examined the correlation of BORIS with a liver stem cell marker (CD90) in HCC tissues by histochemical double staining. The correlation of BORIS with clinicopathologic features and prognosis of HCC was analyzed using patient data. RESULTS: The expression of BORIS was found in SMMC-7721, BEL-7402, and Huh-7, but not in hep-G2 cells. The expression rate of BORIS was significantly higher in the HCC tissues than in the adjacent noncancerous tissues (p=0.000). BORIS expression was correlated with the tumor size (p=0.000), CD90 expression (p=0.000), and satellite nodule (p=0.000). Kaplan-Meier survival curves showed that patients with positive expression of BORIS had lower overall survival rate (p=0.003). CONCLUSIONS: Our data indicate that BORIS may be an auxiliary diagnosis index and a novel favorable prognostic indicator of HCC.
BACKGROUND: The brother of the regulator of imprinted sites (BORIS) is a novel member of the cancer testis antigen gene family, which are normally expressed only in spermatocytes, but abnormally activated in different malignancies. AIM: The aim of this study was to explore the expression of BORIS in hepatocellular carcinoma (HCC) and its correlation with the clinicopathologic features and prognosis of HCC. METHODS: We investigated BORIS expression in HCC cell lines and 105 primary HCC clinical surgical specimens using real-time polymerase chain reaction and Western blot analysis. We further examined the correlation of BORIS with a liver stem cell marker (CD90) in HCC tissues by histochemical double staining. The correlation of BORIS with clinicopathologic features and prognosis of HCC was analyzed using patient data. RESULTS: The expression of BORIS was found in SMMC-7721, BEL-7402, and Huh-7, but not in hep-G2 cells. The expression rate of BORIS was significantly higher in the HCC tissues than in the adjacent noncancerous tissues (p=0.000). BORIS expression was correlated with the tumor size (p=0.000), CD90 expression (p=0.000), and satellite nodule (p=0.000). Kaplan-Meier survival curves showed that patients with positive expression of BORIS had lower overall survival rate (p=0.003). CONCLUSIONS: Our data indicate that BORIS may be an auxiliary diagnosis index and a novel favorable prognostic indicator of HCC.
Authors: Anna Woloszynska-Read; Wa Zhang; Jihnhee Yu; Petra A Link; Paulette Mhawech-Fauceglia; Golda Collamat; Stacey N Akers; Kelly R Ostler; Lucy A Godley; Kunle Odunsi; Adam R Karpf Journal: Clin Cancer Res Date: 2011-02-04 Impact factor: 12.531
Authors: Cyril Cuffel; Jean-Paul Rivals; Yannick Zaugg; Suzanne Salvi; Walter Seelentag; Daniel E Speiser; Danielle Liénard; Philippe Monnier; Pedro Romero; Luc Bron; Donata Rimoldi Journal: Int J Cancer Date: 2010-10-08 Impact factor: 7.396
Authors: Olga Kholmanskikh; Axelle Loriot; Francis Brasseur; Etienne De Plaen; Charles De Smet Journal: Int J Cancer Date: 2008-02-15 Impact factor: 7.396
Authors: Zhen Fan Yang; David W Ho; Michael N Ng; Chi Keung Lau; Wan Ching Yu; Patricia Ngai; Patrick W K Chu; Chi Tat Lam; Ronnie T P Poon; Sheung Tat Fan Journal: Cancer Cell Date: 2008-02 Impact factor: 31.743
Authors: V D'Arcy; N Pore; F Docquier; Z K Abdullaev; I Chernukhin; G-X Kita; S Rai; M Smart; D Farrar; S Pack; V Lobanenkov; E Klenova Journal: Br J Cancer Date: 2008-01-15 Impact factor: 7.640
Authors: Erling A Hoivik; Kanthida Kusonmano; Mari K Halle; Anna Berg; Elisabeth Wik; Henrica M J Werner; Kjell Petersen; Anne M Oyan; Karl-Henning Kalland; Camilla Krakstad; Jone Trovik; Martin Widschwendter; Helga B Salvesen Journal: Oncotarget Date: 2014-02-28
Authors: Sanne Marlijn Janssen; Roy Moscona; Mounib Elchebly; Andreas Ioannis Papadakis; Margaret Redpath; Hangjun Wang; Eitan Rubin; Léon Cornelis van Kempen; Alan Spatz Journal: Cell Death Discov Date: 2020-01-02